173 results on '"Dahle, Jostein"'
Search Results
2. 89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma
3. FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
4. The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest
5. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
6. Bystander Effects May Modulate Ultraviolet A and B Radiation-Induced Delayed Mutagenesis
7. Gap Junctional Intercellular Communication Is not a Major Mediator in the Bystander Effect in Photodynamic Treatment of MDCK II Cells
8. Cooperative Inactivation of Cells in Microcolonies Treated with UVA Radiation
9. Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
10. Cooperative Effects of Photodynamic Treatment of Cells in Microcolonies
11. Modifications in Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameters After α-Particle-Emitting 227Th-trastuzumab Therapy of HER2-Expressing Ovarian Cancer Xenografts
12. Genome-Wide Microarray Analysis of Human Fibroblasts in Response to γ Radiation and the Radiation-Induced Bystander Effect
13. Treatment of HER2-Expressing Breast Cancer and Ovarian Cancer Cells With Alpha Particle-Emitting 227Th-Trastuzumab
14. A 238Pu irradiator for exposure of cultured cells with alpha-radiation: Construction, calibration and dosimetry
15. In Vitro Cytotoxicity of Low-Dose-Rate Radioimmunotherapy by the Alpha-Emitting Radioimmunoconjugate Thorium-227–DOTA–Rituximab
16. FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?
17. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab
18. Overexpression of human OGG1 in mammalian cells decreases ultraviolet A induced mutagenesis
19. Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab
20. Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate
21. Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice
22. Comparing High LET 227Th- and Low LET 177Lu-trastuzumab in Mic with HER-2 Positive SKBR-3 Xenografts
23. Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
24. Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.
25. 89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma.
26. Initial evaluation of 227Th- p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy
27. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
28. Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable.
29. B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-Life
30. NNV024, a Humanized Anti-CD37 Antibody with Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell Malignancies
31. Targeted Alpha-Particle Therapy with 227Th-Labeled Antibodies
32. A one-step method for determining the maximum number of bound antibodies, and the affinity and association rate constants for antibody binding
33. Increased level of oxidative stress in genomically unstable cell clones
34. Melanin Synthesis may Sensitize Melanocytes to Oxidative DNA Damage by Ultraviolet A Radiation and Protect Melanocytes from Direct DNA Damage by Ultraviolet B Radiation
35. Pigmented Melanocytes Are Protected Against Ultraviolet-A-Induced Membrane Damage
36. 177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non- Hodgkin's lymphoma.
37. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003.
38. The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines.
39. 212Pb-NNV003 as a Novel Targeted Alpha Therapy for CD37 Positive B-cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
40. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003.
41. Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
42. Combination of 177Lu‐lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non‐Hodgkin's lymphoma.
43. Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.
44. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
45. Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody–Radionuclide Conjugate.
46. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
47. Combination of 177lutetium-Satetraxetan-Lilotomab and Rituximab Results in Improved Therapeutic Effect in Preclinical Models of Non-Hodgkin Lymphoma
48. Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin®) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)
49. Treatment with 177 lu-HH1 Increases CD20 Expression in Non-Hodgkin Lymphoma Cells in Vitro and In Vivo
50. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.